Abstract
Bone loss is the result of a negative unbalance between bone formation ad bone resorption. In the last years, the studies on the Wnt canonical pathway have highlighted its crucial role in bone balance through its influence on the activity and maturation of the osteoblast line and in the Receptor Activator of Nuclear Factor κ B (RANK) - RANK ligand (RANKL)/Osteoprotegerin (OPG) system. These mechanisms are involved not only in the pathological processes inducing not only systemic bone loss (i.e. Postmenopausal osteoporosis, glucocorticoid- induced osteoporosis, etc.), but also at a local level, as happens in Rheumatoid Arthritis (RA). Recently, several new drugs for the treatment of bone loss have been approved, while some others are still under development. The most promising new drugs in the treatment of osteoporosis include the antibody that neutralizes RANKL (denosumab, DMAb), monoclonal antibodies against sclerostin and parathyroid hormone-related protein analogue. Other new strategies for the prevention and treatment of bone loss include calcilytics, cathepsin K inhibitor or the combination or the sequential use of the current drugs. New insights concerning the treatment of the local bone loss in RA and in Complex Regional Pain Syndrome type I are also provided in this review.
Keywords: Osteoporosis, denosumab, teriparatide, romosozumab, odanacatib, bone loss, combination therapy, rheumatoid arthritis.
Current Pharmaceutical Design
Title:New Strategies for the Prevention and Treatment of Systemic and Local Bone Loss; from Pathophysiology to Clinical Application
Volume: 23 Issue: 41
Author(s): Angelo Fassio*, Maurizio Rossini , Ombretta Viapiana, Luca Idolazzi, Elisabetta Vantaggiato, Camilla Benini and Davide Gatti
Affiliation:
- Unit of Rheumatology, University of Verona, piazzale A. Scuro, Verona,Italy
Keywords: Osteoporosis, denosumab, teriparatide, romosozumab, odanacatib, bone loss, combination therapy, rheumatoid arthritis.
Abstract: Bone loss is the result of a negative unbalance between bone formation ad bone resorption. In the last years, the studies on the Wnt canonical pathway have highlighted its crucial role in bone balance through its influence on the activity and maturation of the osteoblast line and in the Receptor Activator of Nuclear Factor κ B (RANK) - RANK ligand (RANKL)/Osteoprotegerin (OPG) system. These mechanisms are involved not only in the pathological processes inducing not only systemic bone loss (i.e. Postmenopausal osteoporosis, glucocorticoid- induced osteoporosis, etc.), but also at a local level, as happens in Rheumatoid Arthritis (RA). Recently, several new drugs for the treatment of bone loss have been approved, while some others are still under development. The most promising new drugs in the treatment of osteoporosis include the antibody that neutralizes RANKL (denosumab, DMAb), monoclonal antibodies against sclerostin and parathyroid hormone-related protein analogue. Other new strategies for the prevention and treatment of bone loss include calcilytics, cathepsin K inhibitor or the combination or the sequential use of the current drugs. New insights concerning the treatment of the local bone loss in RA and in Complex Regional Pain Syndrome type I are also provided in this review.
Export Options
About this article
Cite this article as:
Fassio Angelo*, Rossini Maurizio , Viapiana Ombretta, Idolazzi Luca , Vantaggiato Elisabetta , Benini Camilla and Gatti Davide, New Strategies for the Prevention and Treatment of Systemic and Local Bone Loss; from Pathophysiology to Clinical Application, Current Pharmaceutical Design 2017; 23 (41) . https://dx.doi.org/10.2174/1381612823666170713104431
DOI https://dx.doi.org/10.2174/1381612823666170713104431 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets Vaccine Therapy Update for Pregnant, Immunocompromised, and Chronic Diseases Patients
Recent Patents on Inflammation & Allergy Drug Discovery Sphingolipids in Inflammation: Roles and Implications
Current Molecular Medicine The Genetic Architecture of Rheumatoid Arthritis: From Susceptibility to Clinical Subphenotype Associations
Current Topics in Medicinal Chemistry Subject Index to Volume 5
Current Pharmaceutical Biotechnology Novel Controlled Release Solid Dispersion for the Delivery of Diclofenac Sodium
Current Drug Delivery Dual COX Inhibition and Upper Gastrointestinal Damage
Current Pharmaceutical Design Administration of Autologous Mesenchymal Cells for the Treatment of Arthritis
Current Stem Cell Research & Therapy Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Current Pharmaceutical Design A Comparative Evaluation of In-Vitro Antioxidant Activity of Some Commonly Used Spices of Northern India
The Natural Products Journal Protease-Activated Receptor 2: Are Common Functions in Glial and Immune Cells Linked to Inflammation-Related CNS Disorders?
Current Drug Targets On the Diversity of Oxidative Bioactivation Reactions on Nitrogen- Containing Xenobiotics
Current Drug Metabolism A Review on the Use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis
Current Drug Targets Innate Immune System Modulation During Aging: Contributions of Macrophages and Dendritic Cells
Current Immunology Reviews (Discontinued) ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Piroxicam: Source for Synthesis of Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Current Pharmaceutical Design Medicinal and Therapeutic Potential of Herbs and Plant Metabolites / Extracts Countering Viral Pathogens - Current Knowledge and Future Prospects
Current Drug Metabolism